# Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

> **NCT05173545** · PHASE1 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Recurrent/Refractory Lymphoma

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome Injection

## Key facts

- **NCT ID:** NCT05173545
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-29
- **Primary completion:** 2020-10-28
- **Final completion:** 2020-10-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05173545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05173545, "Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05173545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*